EFFICACY OF ANTIDEPRESSANTS IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5878Keywords:
Irritable Bowel Syndrome; Antidepressants; Gut–Brain Interaction; Tricyclic Antidepressants; Selective Serotonin Reuptake Inhibitors; Serotonin-Norepinephrine Reuptake Inhibitors NeuromodulatorsAbstract
Background: Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which antidepressants are used to modulate pathways involved in symptom generation. Evidence for their efficacy remains heterogeneous across drug classes and outcomes.
Aim: To systematically evaluate the efficacy of antidepressants in the treatment of IBS across pharmacological classes and outcome domains.
Methods: The methodology and reporting structure of this review were informed by the PRISMA framework. Literature searches were conducted in PubMed and Google Scholar to identify studies evaluating antidepressants in adults with irritable bowel syndrome diagnosed according to Rome criteria. Randomized controlled trials were considered the primary source of evidence and were supplemented, where relevant, by open-label, mechanistic, and exploratory studies. Eligible studies reported validated clinical outcomes, including IBS symptom severity, abdominal pain, global improvement, and health-related quality of life. Owing to differences in study design, interventions, and outcome measures, findings were synthesized qualitatively.
Results: Tricyclic antidepressants (TCAs) demonstrated the most consistent signal of benefit, particularly for IBS symptom severity, global improvement, and abdominal pain. Selective serotonin reuptake inhibitors (SSRIs) showed inconsistent findings across trials, with effects varying by outcome measure and study design. Evidence for serotonin–norepinephrine reuptake inhibitors (SNRIs) was limited, often derived from add-on or open-label studies, although some randomized trials reported improvements in symptom severity and quality of life. Data for other antidepressants were restricted to a small number of RCTs with endpoint-specific effects. Variability in outcome measures, including IBS-SSS, adequate relief, and quality-of-life instruments, contributed to heterogeneity in reported treatment effects.
Conclusions: Antidepressants appear to have a role in IBS management, with the most consistent evidence observed for TCAs. Findings for SSRIs are inconclusive, while evidence for SNRIs and other agents remains limited. Interpretation is constrained by variability in outcome measures and study design. Further well-designed RCTs using standardized endpoints are required to better define the role of antidepressants in IBS.
References
Abdul-Baki, H., El Hajj, I. I., Elzahabi, L., Azar, C., Aoun, E., Skoury, A., Chaar, H., & Sharara, A. I. (2009). A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World Journal of Gastroenterology, 15(29), 3636–3642. https://doi.org/10.3748/wjg.15.3636
Black, C. J., Yuan, Y., Selinger, C. P., Camilleri, M., Quigley, E. M. M., Moayyedi, P., & Ford, A. C. (2020). Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: A systematic review and network meta-analysis. The Lancet Gastroenterology & Hepatology, 5(2), 117–131. https://doi.org/10.1016/S2468-1253(19)30324-3
Brennan, B. P., Fogarty, K. V., Roberts, J. L., Reynolds, K. A., Pope, H. G., Jr., & Hudson, J. I. (2009). Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study. Human Psychopharmacology, 24(5), 423–428. https://doi.org/10.1002/hup.1038
Chial, H. J., Camilleri, M., Ferber, I., Delgado-Aros, S., Burton, D., McKinzie, S., & Zinsmeister, A. R. (2003). Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clinical Gastroenterology and Hepatology, 1(3), 211–218. https://doi.org/10.1053/jcgh.2003.50031
Drossman, D. A. (2016). Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology, 150(6), 1262–1279. https://doi.org/10.1053/j.gastro.2016.02.032
Ford, A. C., Lacy, B. E., Harris, L. A., Quigley, E. M. M., & Moayyedi, P. (2019). Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis. The American Journal of Gastroenterology, 114(1), 21–39. https://doi.org/10.1038/s41395-018-0222-5
Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P. L., Ridd, M. J., Foy, R., Bianco, G., Bishop, F. L., Chaddock, M., Cook, H., Cooper, D., Fernandez, C., Guthrie, E. A., Hartley, S., Herbert, A., Howdon, D., Muir, D. P., Nath, T., Newman, S., Smith, T., . . . ATLANTIS Trialists. (2023). Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10414), 1773–1785. https://doi.org/10.1016/S0140-6736(23)01523-4
Han, C., Masand, P. S., Krulewicz, S., Peindl, K., Mannelli, P., Varia, I. M., Pae, C. U., & Patkar, A. A. (2009). Childhood abuse and treatment response in patients with irritable bowel syndrome: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. Journal of Clinical Pharmacy and Therapeutics, 34(1), 79–88. https://doi.org/10.1111/j.1365-2710.2008.00975.x
Kaplan, A., Franzen, M. D., Nickell, P. V., Ransom, D., & Lebovitz, P. J. (2014). An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice, 18(1), 11–15. https://doi.org/10.3109/13651501.2013.838632
Khalilian, A., Ahmadimoghaddam, D., Saki, S., Mohammadi, Y., & Mehrpooya, M. (2021). A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. BioPsychoSocial Medicine, 15(1), Article 3. https://doi.org/10.1186/s13030-021-00205-2
Kilkens, T. O., Honig, A., Fekkes, D., & Brummer, R. J. (2005). The effects of an acute serotonergic challenge on brain–gut responses in irritable bowel syndrome patients and controls. Alimentary Pharmacology & Therapeutics, 22(9), 865–874. https://doi.org/10.1111/j.1365-2036.2005.02660.x
Kuiken, S. D., Tytgat, G. N., & Boeckxstaens, G. E. (2003). The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Clinical Gastroenterology and Hepatology, 1(3), 219–228. https://doi.org/10.1053/cgh.2003.50032
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021). ACG clinical guideline: Management of irritable bowel syndrome. The American Journal of Gastroenterology, 116(1), 17–44. https://doi.org/10.14309/ajg.0000000000001036
Ladabaum, U., Sharabidze, A., Levin, T. R., Zhao, W. K., Chung, E., Bacchetti, P., Jin, C., Grimes, B., & Pepin, C. J. (2010). Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology, 8(1), 42–48.e1. https://doi.org/10.1016/j.cgh.2009.09.008
Lewis-Fernández, R., Lam, P., Lucak, S., Galfalvy, H., Jackson, E., Fried, J., Rosario, M., de la Cruz, A. A., Sánchez-Lacay, A., Díaz, S., & Schneier, F. (2016). An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder. Journal of Clinical Psychopharmacology, 36(6), 710–715. https://doi.org/10.1097/JCP.0000000000000599
Marks, D. M., Han, C., Krulewicz, S., Pae, C. U., Peindl, K., Patkar, A. A., & Masand, P. S. (2008). History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: Post hoc analysis from a placebo-controlled study. Primary Care Companion to the Journal of Clinical Psychiatry, 10(5), 368–375. https://doi.org/10.4088/pcc.v10n0504
Masand, P. S., Pae, C. U., Krulewicz, S., Peindl, K., Mannelli, P., Varia, I. M., & Patkar, A. A. (2009). A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics, 50(1), 78–86. https://doi.org/10.1176/appi.psy.50.1.78
Mayer, E. A., Savidge, T., & Shulman, R. J. (2014). Brain–gut microbiome interactions and functional bowel disorders. Gastroenterology, 146(6), 1500–1512. https://doi.org/10.1053/j.gastro.2014.02.037
Morgan, V., Pickens, D., Gautam, S., Kessler, R., & Mertz, H. (2005). Amitriptyline reduces rectal pain-related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut, 54(5), 601–607. https://doi.org/10.1136/gut.2004.047423
Oka, P., Parr, H., Barberio, B., Black, C. J., Savarino, E. V., & Ford, A. C. (2020). Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5(10), 908–917. https://doi.org/10.1016/S2468-1253(20)30217-X
Purshottam, V., Tripathi, A., Gupta, B., & Rungta, S. (2025). A randomized double-blind placebo-controlled trial of add-on duloxetine on symptom severity and quality of life in irritable bowel syndrome. Indian Journal of Behavioural Sciences, 28, 1–9. https://doi.org/10.4103/IJBS.IJBS_14_24
Rao, S. S. C., Coss-Adame, E., Yan, Y., Erdogan, A., Valestin, J., & Ayyala, D. N. (2021). Sensory adaptation training or escitalopram for IBS with constipation and rectal hypersensitivity: A randomized controlled trial. Clinical and Translational Gastroenterology, 12(7), e00381. https://doi.org/10.14309/ctg.0000000000000381
Salehian, R., Mokhtare, M., Ghanbari Jolfaei, A., & Noorian, R. (2021). Investigation of the effectiveness of duloxetine in quality of life and symptoms of patients with irritable bowel syndrome. Advanced Biomedical Research, 10, Article 14. https://doi.org/10.4103/abr.abr_247_20
Seddighnia, A., Tadayon Najafabadi, B., Ghamari, K., Noorbala, A. A., Ebrahimi Daryani, N., Kashani, L., & Akhondzadeh, S. (2020). Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics, 45(1), 97–104. https://doi.org/10.1111/jcpt.13032
Sharbafchi, M. R., Afshar, H., Adhamian, P., Feizi, A., Daghaghzadeh, H., & Adibi, P. (2020). Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome. Journal of Research in Medical Sciences, 25, Article 115. https://doi.org/10.4103/jrms.JRMS_699_19
Tack, J., Broekaert, D., Fischler, B., Van Oudenhove, L., Gevers, A. M., & Janssens, J. (2006). A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut, 55(8), 1095–1103. https://doi.org/10.1136/gut.2005.077503
Talley, N. J., Kellow, J. E., Boyce, P., Tennant, C., Huskic, S., & Jones, M. (2008). Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. Digestive Diseases and Sciences, 53(1), 108–115. https://doi.org/10.1007/s10620-007-9830-4
Thoua, N. M., Murray, C. D., Winchester, W. J., Roy, A. J., Pitcher, M. C., Kamm, M. A., & Emmanuel, A. V. (2009). Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 29(5), 552–560. https://doi.org/10.1111/j.1365-2036.2008.03918.x
Vahedi, H., Merat, S., Rashidioon, A., Ghoddoosi, A., & Malekzadeh, R. (2005). The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A double-blind randomized controlled study. Alimentary Pharmacology & Therapeutics, 22(5), 381–385. https://doi.org/10.1111/j.1365-2036.2005.02566.x
Vork, L., Mujagic, Z., Drukker, M., Keszthelyi, D., Conchillo, J. M., Hesselink, M. A. M., van Os, J., Masclee, A. A. M., Leue, C., & Kruimel, J. W. (2019). The Experience Sampling Method—evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. Neurogastroenterology & Motility, 31(1), e13515. https://doi.org/10.1111/nmo.13515
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Marzena Chrapczyńska, Agnieszka Filarecka, Piotr Przybyszewski, Emilia Przybyszewska, Julia Gatniejewska, Martyna Sienicka, Paulina Prudzic, Weronika Winiarska, Wiktoria Bełcikowska-Skowron, Aleksandra Siegmund
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
